Explore

Trendline Trendline
Merck Discontinues TROP ADC Development Amid Strategic Shifts

Merck Discontinues TROP ADC Development Amid Strategic Shifts

Merck Discontinues TROP ADC Development Amid Strategic Shifts
Trendline Trendline
Merck Discontinues Early-Stage TROP ADC Amid Strategic Shifts in Oncology

Merck Discontinues Early-Stage TROP ADC Amid Strategic Shifts in Oncology

Merck Discontinues Early-Stage TROP ADC Amid Strategic Shifts in Oncology
Reuters Reuters
Big Pharma M&A set for mega year as patent expiries drive deal urgency

Big Pharma M&A set for mega year as patent expiries drive deal urgency

By Christy Santhosh and Sriparna Roy May 1 (Reuters) - Biotech dealmaking is on pace for a bumper year in 2026, with large drugmakers on an acquisition spree to boost their pipelines ahead of upcoming patent losses.
Trendline Trendline
Avalyn Pharma Targets $300 Million in Upscaled IPO for Respiratory Therapies

Avalyn Pharma Targets $300 Million in Upscaled IPO for Respiratory Therapies

Avalyn Pharma Targets $300 Million in Upscaled IPO for Respiratory Therapies
Trendline Trendline
Bicycle Therapeutics Reports Q1 2026 Financial Results, Highlights Progress in Cancer Therapies

Bicycle Therapeutics Reports Q1 2026 Financial Results, Highlights Progress in Cancer Therapies

Bicycle Therapeutics Reports Q1 2026 Financial Results, Highlights Progress in Cancer Therapies
Trendline Trendline
Bicycle Therapeutics Advances Cancer Drug Development with Promising Clinical Data

Bicycle Therapeutics Advances Cancer Drug Development with Promising Clinical Data

Bicycle Therapeutics Advances Cancer Drug Development with Promising Clinical Data
Trendline Trendline
Merck Reports Strong Q1 Results Driven by Keytruda Sales, Adjusts 2026 Outlook

Merck Reports Strong Q1 Results Driven by Keytruda Sales, Adjusts 2026 Outlook

Merck Reports Strong Q1 Results Driven by Keytruda Sales, Adjusts 2026 Outlook
Trendline Trendline
Bambusa Therapeutics Completes Enrollment for Phase 1b/2a Trial of BBT001 for Atopic Dermatitis

Bambusa Therapeutics Completes Enrollment for Phase 1b/2a Trial of BBT001 for Atopic Dermatitis

Bambusa Therapeutics Completes Enrollment for Phase 1b/2a Trial of BBT001 for Atopic Dermatitis
Trendline Trendline
Amylyx Pharmaceuticals to Announce Q1 2026 Financial Results Amid Strategic Focus on Neurodegenerative Diseases

Amylyx Pharmaceuticals to Announce Q1 2026 Financial Results Amid Strategic Focus on Neurodegenerative Diseases

Amylyx Pharmaceuticals to Announce Q1 2026 Financial Results Amid Strategic Focus on Neurodegenerative Diseases
Trendline Trendline
Bambusa Therapeutics Completes Enrollment for Atopic Dermatitis Drug Trial

Bambusa Therapeutics Completes Enrollment for Atopic Dermatitis Drug Trial

Bambusa Therapeutics Completes Enrollment for Atopic Dermatitis Drug Trial
Trendline Trendline
Corcept Therapeutics Reports Q1 2026 Financial Results and FDA Approval of New Cancer Treatment

Corcept Therapeutics Reports Q1 2026 Financial Results and FDA Approval of New Cancer Treatment

Corcept Therapeutics Reports Q1 2026 Financial Results and FDA Approval of New Cancer Treatment
Trendline Trendline
Bicycle Therapeutics Reports Strategic Reprioritization and Financial Results for Q1 2026

Bicycle Therapeutics Reports Strategic Reprioritization and Financial Results for Q1 2026

Bicycle Therapeutics Reports Strategic Reprioritization and Financial Results for Q1 2026